Illumina ILMN announced today that the company has filed a new patent
infringement suit against Ariosa Diagnostics, Inc. Illumina is seeking all
available remedies, including injunctive relief.
The new suit, filed in the U.S. District Court for the Northern District of
California, is based on Ariosa's infringement of U.S. Patent No. 7,955,794,
entitled “Multiplex Nucleic Acid Reactions.” The suit targets Ariosa's
Harmony™ Prenatal Test, including its use of digital analysis of selected
regions (DANSR) that, among other things, enables simultaneous quantification
of hundreds of DNA loci.
Verinata Health, now a wholly owned subsidiary of Illumina, previously sued
Ariosa for infringement of U.S. Patent No. 8,296,076 and U.S. Patent No.
8,318,430 in the U.S. District Court for the Northern District of California.
The Court in that case issued a Claim Construction Order providing the Court's
interpretation of the disputed patent terms which supports the position that
Ariosa infringes those patents.
Illumina offers the verifi® non-invasive prenatal test (formerly offered by
Verinata Health) in its CLIA-certified, CAP-accredited clinical services
laboratory, to detect chromosome abnormalities and aberrations with improved
resolution for consistent and dependable results. verifi® is the broadest
non-invasive prenatal test available today and is part of Illumina's
comprehensive reproductive and genetic health portfolio.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in